ArticleGland surgery2026
Local recurrence in nipple-sparing mastectomy without intraoperative radiotherapy (IORT) in breast cancer.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nipple-sparing mastectomy (NSM) is increasingly used in breast cancer treatment. Concerns remain about residual tissue beneath the nipple-areolar complex (NAC) and the risk of locoregional recurrence (LRR). This study aimed to evaluate recurrence in NSM patients with or without radiation therapy (RT) and to assess the role of RT. Methods: Retrospective review of patients with ductal carcinoma in situ (DCIS) or invasive breast cancer who underwent NSM with immediate reconstruction without intraoperative radiotherapy (IORT) from January 2007 to July 2021. LRR was the primary outcome; secondary outcomes included overall survival (OS), disease-free survival (DFS), and factors associated with outcomes and RT use. Results: A total of 148 NSMs were analyzed, including 116 invasive cancers and 33 DCIS cases. The mean age was 43 years, most patients were premenopausal (80%), T1 to T2 (94%), node-negative (64%), and estrogen receptor (ER) positive (82%). Positive margins occurred in 10 patients (7%). Chemotherapy was administered to 91 (68%), hormonal therapy to 118 (83%), and trastuzumab to half of 21 human epidermal growth factor receptor 2 (HER2) positive patients. Whole breast RT was given to 42 patients (28%). After a median follow-up of 72 months, 9 patients (6%) experienced LRR. RT did not significantly affect recurrence or survival. Ten-year OS was 100% Conclusions: NSM without IORT is safe, and selective RT guided by tumor, nodal, and margin status achieves low LRR, even in higher-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.